Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Deffered Revenue (2016 - 2026)

Ocular Therapeutix has reported Non-Current Deffered Revenue over the past 13 years, most recently at $14.0 million for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $14.0 million; the TTM value through Mar 2026 reached $14.0 million, changed 0.0%, while the annual FY2025 figure was $14.0 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2026 was $14.0 million at Ocular Therapeutix, roughly flat from $14.0 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $14.3 million in Q2 2023 and troughed at $13.0 million in Q2 2022.
  • A 5-year average of $13.8 million and a median of $14.0 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: rose 12.78% in 2022 and later fell 1.78% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $13.4 million in 2022, then rose by 5.59% to $14.1 million in 2023, then decreased by 0.96% to $14.0 million in 2024, then changed by 0.0% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
  • Business Quant data shows Non-Current Deffered Revenue for OCUL at $14.0 million in Q1 2026, $14.0 million in Q4 2025, and $14.0 million in Q3 2025.